Hepatocellular carcinoma Hepatocellular carcinoma
Conditions
Interventions
After local therapy (radiofrequency ablation, radiation therapy, hepatic arterial chemoembolization, or hepatic arterial chemotherapy), a single dose of 1500 mg durvalumab and 300 mg tremelimumab is a
Local therapy, STRIDE, Durvalmab, Tremelimumab
Sponsors
Yamashita Taro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) clinically diagnosed as hepatocellular carcinoma 2) unsuitable for radical local therapy due to biloblar multiple nodules, ductal invasion, metastatic lesions, or other factors 3) previously treated by one or more systemic therapy 4) target lesion for paliative local therapy 5) preserved liver function 6) 18 years or older 7) ECOG Performance status <=2 8) preservation of major organ function 9) written informed consent
Exclusion criteria
Exclusion criteria: 1) refractory ascites or pleural effusion 2) unsuitable for paliative local therapy 3) risky varices without prophylactic procedures 4) double cancer 5) metastases to central nervous system 6) severe complication 7) active infectious disease 8) pregnant or lactating women, or women of childbearing potential 9) mental disorder 10) patients who investigator regards as inappropriate for candidate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological response, Objective response rate, Tumor control rate, Overall survival, Subsequent therapy, Adverse events | — |
Contacts
Public ContactTakeshi Terashima
Kanazawa University Hospital
Outcome results
None listed